All articles tagged with #rsv vaccine
The US has revised its childhood vaccine schedule, now recommending fewer vaccines for flu, hepatitis A and B, and RSV, aligning with peer countries, and bypassing the usual approval process, under Health Secretary Robert F. Kennedy Jr.'s initiatives.
Emerging evidence suggests that vaccines, especially the shingles vaccine, may reduce the risk of dementia by preventing infections that accelerate brain aging and possibly through immune system stimulation, offering a promising new avenue for dementia prevention alongside lifestyle changes.
The American College of Obstetricians and Gynecologists (ACOG) recommends COVID-19, flu, and RSV vaccines for pregnant women, diverging from CDC guidance, emphasizing the safety and protective benefits of vaccination during pregnancy to reduce severe illness and protect newborns, especially during the upcoming respiratory season.
The American College of Obstetricians and Gynecologists (ACOG) has updated its guidelines to strongly recommend vaccination during pregnancy against COVID-19, influenza, and RSV, emphasizing the safety and benefits of maternal immunization for protecting both mothers and infants, including passive immunity for newborns and reduced pregnancy complications.
A UK study shows that vaccinating pregnant women against RSV results in a 72% decrease in severe RSV hospitalizations in infants by transferring protective antibodies through the placenta, highlighting the importance of increasing vaccination rates among expectant mothers to protect newborns during the winter season.
A large US study suggests that the shingles vaccine (Shingrix) and the RSV vaccine (Arexyv) are associated with a reduced risk of dementia in older adults, potentially due to the immune-boosting adjuvant they contain, indicating vaccines might protect against cognitive decline beyond preventing specific viruses.
Health Secretary Robert F. Kennedy Jr. approved an expansion of CDC's RSV vaccine recommendations to include adults aged 50-59 at high risk, after firing the original advisory committee members. This move benefits vaccine makers Moderna and Pfizer, whose shares rose following the announcement, and reflects ongoing vaccine regulation despite Kennedy's disruptions to the public health apparatus.
Moderna's stock rose after CDC recommended its RSV vaccine for at-risk adults aged 50-59, aligning with previous advisory panel recommendations, despite earlier uncertainties following Robert F. Kennedy Jr.'s decision to replace the advisory panel. This expands Moderna's market for the vaccine, which competes with Pfizer and GSK, and signals potential future growth despite past sales misses.
The FDA has expanded Moderna's RSV vaccine approval to include adults under 60 at increased risk, pending CDC advisory committee approval, marking a significant step in protecting more vulnerable populations from severe RSV illness.
Moderna reported a surprise profit in the third quarter, driven by strong Covid vaccine sales, but its stock fell after initial gains. The company's RSV vaccine sales were significantly below expectations, contributing to a cautious outlook. Despite the unexpected profit, analysts predict continued losses as Moderna invests in its product portfolio. The company plans to seek FDA approval for new vaccines but faces challenges in a competitive market. Moderna's stock has declined significantly since its peak earlier this year.
Moderna reported a surprise third-quarter profit of $13 million, driven by higher-than-expected sales of its COVID-19 vaccine, Spikevax, which generated $1.8 billion in revenue. This exceeded analysts' expectations and marked a significant turnaround from a $3.6 billion loss a year ago. Despite the profit, Moderna anticipates lower COVID vaccine sales this year compared to 2023 and reaffirmed its 2024 sales forecast of $3 billion to $3.5 billion. Sales of its new RSV vaccine fell short of expectations, contributing only $10 million.
Moderna reported a surprise profit of $13 million for the third quarter, driven by higher-than-expected Covid vaccine sales and significant cost-cutting measures. The company's revenue reached $1.86 billion, surpassing Wall Street expectations. Moderna's efforts to reduce expenses include a goal of saving $1.1 billion by 2027. The quarter also marked the first sales of its RSV vaccine, though these were lower than anticipated. Moderna plans to expand its product offerings, including a next-generation Covid vaccine and a combination shot targeting Covid and flu.
The US FDA has approved Moderna's RSV vaccine, mRESVIA, for adults aged 60 and older, with a label indicating 79% efficacy, lower than the 84% initially reported. This approval marks the first non-COVID-19 mRNA vaccine in the US. Moderna aims to generate new revenue as demand for its COVID-19 vaccine declines, with analysts forecasting significant sales growth for the RSV vaccine in the coming years. The CDC will vote on usage recommendations next month.
The FDA has approved Moderna's RSV vaccine, mResvia, for adults aged 60 and older, marking the company's second licensed product. The vaccine, which uses the same mRNA platform as Moderna's Covid-19 vaccine, showed an efficacy of 83.7% in trials and had no serious safety concerns. This approval follows the earlier market entry of RSV vaccines from GSK and Pfizer. The CDC's Advisory Committee on Immunization Practices will next review the vaccine for recommendations.
Moderna's stock fell after the FDA approved its second product, an RSV vaccine named mResvia, which targets respiratory syncytial virus in older adults. This approval further validates Moderna's mRNA technology, also used in its Covid vaccine. Despite the stock dip, analysts project significant future sales growth for the RSV vaccine, potentially giving Moderna an edge over competitors Pfizer and GSK. Moderna's pre-filled syringe for the vaccine could simplify administration in pharmacies, enhancing its market position.